CD274 and Miyoshi myopathy: In addition, recent data from Bar et al. (34) on a pilot trial of single agent anti-PD-L1, atezolizumab, in asymptomatic MM patients, revealed a specific in vivo rapid expansion and activation of myeloid cells, and T cell reinvigoration after treatment.